MedTrace Logo

CP-675,206 In Patients With Advanced Melanoma

NCT00086489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2012-06-06

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma

Conditions

  • Malignant Melanoma

Interventions

DRUG

CP-675,206

pts treated at 10 mg/kg dose level on a monthly regimen

DRUG

CP-675,206

pts treated at 15 mg/kg dose level on a quarterly regimen

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2007-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00086489 on ClinicalTrials.gov